Galcanezumab
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Galcanezumab: From Migraine to Heparin Cofactor 2 Deficiency
One-Sentence Summary
Galcanezumab is a monoclonal antibody that neutralizes CGRP (calcitonin gene-related peptide), a class used for migraine. The source data does not list its approved indications, so migraine is inferred from the CGRP mechanism. The TxGNN model predicts it may be effective for heparin cofactor 2 deficiency, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model-only prediction, and no plausible mechanistic link has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the US license records (migraine inferred from the CGRP mechanism) |
| Predicted New Indication | Heparin cofactor 2 deficiency |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 (all entries are BLA761063) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Based on known pharmacology, galcanezumab is a monoclonal antibody that neutralizes CGRP, a neuropeptide involved in migraine and vasodilation.
Heparin cofactor 2 is a serpin that inhibits thrombin, mainly through dermatan sulfate. CGRP signaling has no known role in this pathway, so no plausible mechanistic link was identified. The high score (0.995) is a graph-based prediction only. It cannot be checked against known pharmacology because the source lacks the drug’s original indications and mechanism.
The two other top-ranked predictions show the same pattern:
| Rank | Predicted Indication | TxGNN Score | Assessment |
|---|---|---|---|
| 2 | Antithrombin deficiency type 2 | 99.41% | No mechanistic link. Treatment is anticoagulation or antithrombin replacement, unrelated to CGRP blockade. |
| 3 | Factor 5 excess with spontaneous thrombosis | 99.41% | No mechanistic link. CGRP-pathway inhibitors also raise a vascular-tone and cardiovascular safety question in a thrombosis-prone population. |
All three predictions are likely knowledge-graph artifacts: they have no trials or literature, and all are graded L5 and Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761063 | EMGALITY (Eli Lilly and Company) | Injection, solution | Not listed in source data |
The record contains three entries under the same authorization number, with the same product and dosage form. The only route is injectable.
Safety Considerations
Please refer to the package insert for safety information.
No drug-interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The three predictions rest only on a graph-model score, with no trials, no literature, and no plausible mechanistic link to coagulation-pathway deficiencies. The safety data is also incomplete, so no safety screening is possible.
To proceed, the following is needed:
- The package insert (warnings, contraindications, approved indications), from the FDA website
- Mechanism of action data, from DrugBank
- Any preclinical or mechanistic evidence connecting CGRP blockade to the heparin cofactor 2 or antithrombin pathways
- A cardiovascular and thrombosis safety assessment before considering any use in thrombosis-prone populations
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.